← All Nutra Pharma CORP filings

Nutra Pharma CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

OTC.Pink
NPHC
Nutra Pharma CORP
10-K: Nutra Pharma Corp. 2025 Annual Report Analysis
Nutra Pharma Corp. reports significant net losses and substantial doubt regarding its ability to continue as a going concern in its 2025 annual report.
OTC.Pink
NPHC
Nutra Pharma CORP
10-K: Nutra Pharma Faces Going Concern Doubt Amid Losses, SEC Settlement
Nutra Pharma Corp. reported continued net losses and a significant working capital deficit for fiscal year 2024, raising substantial doubt about its ability to continue as a going concern, while also settling a major SEC lawsuit.
OTC.Pink
NPHC
Nutra Pharma CORP
10-K: Nutra Pharma Reports 2023 Loss Amid SEC Settlement, Leadership Change
Nutra Pharma Corp. reported a net loss of $1.39 million in 2023, a significant decline from the prior year's net income, while settling an SEC lawsuit and undergoing a CEO transition.
OTC.Pink
NPHC
Nutra Pharma CORP
10-K: Nutra Pharma Reports 2022 Net Income Amidst SEC Settlement, Leadership Change
Nutra Pharma Corp. reported a net income of $8.18 million for 2022, primarily driven by a non-cash gain from derivative revaluation, while facing a significant SEC settlement and a change in executive leadership.